⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374406 | 1.00 | — | — | |
| SCHEMBL17164052 | 0.98 | NPC1 (0.47) | — | |
| SCHEMBL5563364 | 0.82 | CYP1A2 (0.50) | — | |
| SCHEMBL690354 | 0.78 | EGFR (0.52) | — | |
| SCHEMBL30044827 | 0.76 | — | — | |
| SCHEMBL564890 | 0.76 | — | — | |
| SCHEMBL2174911 | 0.76 | NPC1 (0.45) | — | |
| SCHEMBL1531644 | 0.76 | MEN1 (0.49) | — | |
| SCHEMBL374260 | 0.76 | EGFR (0.53) | — | |
| Hydrochloric Acid SCHEMBL5574787 | 0.74 | KMT2A (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676486-A1 | METHODS OF TREATING SKELETAL DYSPLASIAS | QED Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025090870-A1 | INFIGRATINIB AND METABOLITES THEREOF FOR USE IN METHODS OF TREATING SKELETAL DISORDERS | QED THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2024186882-A1 | METHODS OF TREATING SKELETAL DYSPLASIAS | QED THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240199603-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-06-20 | — | — | US | disclosed |
| CN-117982507-A | Use of inflictinib in the treatment of gastric and adenocarcinoma | QED医药股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-11926625-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4262774-A1 | METHODS OF TREATING ACHONDROPLASIA | QED Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116887822-A | Method for treating achondroplasia | 奎德治疗学股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
| WO-2022133212-A1 | METHODS OF TREATING ACHONDROPLASIA | QED THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-3976042-A2 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976833-A1 | METHODS OF TREATING URINARY SYSTEM CANCERS | QED Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114144180-A | Method for treating bile duct cancer | QED医药股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| WO-2020243273-A9 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |